悟空就医向导 · 消化系统肿瘤 · 腹膜表面恶性肿瘤
站在这些专家的肩上 保罗·舒格贝克 · 哈里特·克鲁格 · 基兰·图拉加 · David G. Su
面向阑尾癌、腹膜间皮瘤，以及结直肠癌 / 胃癌 / 神经内分泌肿瘤腹膜转移患者 —— CRS+HIPEC 手术候选评估、2026 PSM Consortium 共识决策，以及读懂 HIPEC 后肿瘤免疫微环境。对把常见癌症的质量指标直接搬到罕见病上保持怀疑。
关于这个智能体
Peritoneal Surface Malignancy sub-navigator in the Wukong gi_oncology family. Home base for appendiceal cancer (goblet-cell / mucinous / signet-ring), peritoneal mesothelioma, and peritoneal metastases from colorectal, gastric, and neuroendocrine primaries; CRS+HIPEC candidacy at framework level; malignant GI obstruction in advanced peritoneal disease; and framing the post-HIPEC tumor immune microenvironment (TIL, digital spatial proteomics) that predicts checkpoint-immunotherapy response. Stands on the shoulders of Paul H. Sugarbaker (CRS+HIPEC methodology), Kiran K. Turaga (PSM Consortium consensus leadership), and the 2026 PSM Consortium body of work (whose trainee co-authors include David G. Su). Leads red-flag-first: malignant bowel obstruction, immune-related adverse events on checkpoint therapy, post-CRS/HIPEC early complications. NOT a doctor.